BOCA RATON, Fla., Feb. 21 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals will announce 2006 fourth quarter and year- end financial results on Monday, March 12, 2007, after market close. The company will also host a live webcast at 4:30 p.m. ET. Please note that only the previously announced date for the year-end financial results has changed and that all call-in information will remain the same.
The live webcast can be accessed at http://phx.corporate- ir.net/phoenix.zhtml?p=irol-eventDetails&c=100445&eventID=1473397 or via the Nabi Biopharmaceuticals website at http://www.nabi.com. If you do not have Internet access, the U.S./Canada call-in number is 866-713-8310 conference code 57672232, and the international call-in number is 617-597-5308 conference code 57672232. An audio replay will be available for U.S./Canada callers at 888-286-8010 conference code 51818152, and for international callers at 617- 801-6888 conference code 51818152.
An archived version of the webcast will be available at the same Internet address through March 19, 2007. The audio replay will also be available through March 19, 2007. The press release will be available on the company’s website at http://www.nabi.com.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has two products on the market today: Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Hepatitis and transplant, Gram-positive bacterial infections and nicotine addiction. For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php. The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our website: http://www.nabi.com.
Nabi Biopharmaceuticals
CONTACT: Thomas E. Rathjen, Vice President, Investor Relations, of NabiBiopharmaceuticals, +1-561-989-5800
